We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.

Accept

United States

Choose your country or region:

DIGITAL NEWSROOM

Featured post

May 19, 2021

New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer

Exact Sciences today announced results from a health economic analysis of the Oncotype DX Breast Recurrence Score® test, accepted at the 2021 American Society…

Read more »

Featured post

May 19, 2021

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced new data on its cancer tests and treatment guidance tools will be showcased in seven…

Read more »

Featured post

May 19, 2021

Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45

National Task Force supports Cologuard® as a screening option and screening expands to an additional ˜19 million Americans MADISON, Wis. – May 18, 2021 – The United States ...

Read more »